PLUS THERAPEUTICS, INC.

Regulatory Filings • Apr 30, 2012

8-K 1 cytori8k_04302012.htm CYTORI THERAPEUTICS FORM 8K_04.30.2012 cytori8k_04302012.htm Licensed to: Cytori Therapeutics, Inc. Document Created using EDGARizer 2020 5.4.1.0 Copyright 1995 - 2009 Thomson Reuters. All rights reserved.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 30, 2012

CYTORI THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-34375	33-0827593
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

3020 Callan Road, San Diego, California 92121

(Address of principal executive offices, with zip code)

(858) 458-0900

(Registrant's telephone number, including area code)

n/a

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

EFPlaceholder

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

EFPlaceholder

EFPlaceholder Item 1.02 Termination of a Material Definitive Agreement.

On April 30, 2012 the Company terminated its Common Stock Purchase Agreement dated July 11, 2011 with Seaside 88 LP (the “Agreement”). A detailed description of the terms of the Agreement was reported in a current report on Form 8-K, filed with the SEC on July 12, 2011, and is incorporated herein by reference. The Agreement was terminable by the Company at any time in its sole discretion without penalty. The effect of the termination of the Agreement at this time, is that the Company will not sell the remaining and final 500,000 shares that would otherwise have been sold under the Agreement this week.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CYTORI THERAPEUTICS, INC.
Date: April 30, 2012	By: /s/ Mark E. Saad
	Mark E. Saad
	Chief Financial Officer